A Possible Distinct Molecular Subtype (Quintuple-Wildtype) of Metastatic Colorectal Cancer in First-Line Anti-EGFR Therapy with Cetuximab Plus FOLFIRI - Palliative Precision Therapy and a Multidisciplinary Treatment Approach: Interim Analysis of the IVOPAK II Trial with Early Results

CONCLUSION: Initial results of this new biomarker panel (quintuple-wildtype) are promising for anti-EGFR therapy with cetuximab plus doublet chemotherapy (FOLFIRI) in first-line treatment of metastatic CRC. These results warrant confirmation with higher case numbers in the IVOPAK II trial.PMID:34670215 | DOI:10.1159/000519252

Source: Oncology - October 20, 2021 Category: Cancer & Oncology Authors: Axel Wein Robert Stoehr Stephan Kersting J ürgen Siebler Susanne Merkel Dagmar Busse Kerstin Wolff Nicola Ostermeier Clemens Neufert Francesco Vitali Markus Eckstein Jan-Peter Roth Peter Anhut Waldemar Schreiner Michael Uder Arndt Hartmann Markus F Neura Source Type: research